Company intelligence / Profile preview

Lyme Diagnostics

Ownership: Private
Development stage: Other

Overview

Lyme Diagnostics Ltd. has developed a fully automated diagnostic device for the direct detection of Borrelia burgdorferi, the bacterium responsible for Lyme disease. The technology enables early and fast testing at any stage of infection and has been validated in a European clinical trial. The device received IVD CE marking and is ready for distribution across Europe. The method builds on 35 years of research by Dr. Bózsik.

Therapeutic areas: Infectious Diseases
Modalities: DeviceDiagnostic test
Industry: Molecular Diagnostics

Beyond the preview

Go deeper on Lyme Diagnostics.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Lyme Diagnostics.

Explore the full profile